Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis

Published:2017-05-24 Issue:9 Volume:47 Page:832-839
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Furuse Junji¹²,Gemma Akihiko²³,Ichikawa Wataru²⁴,Okusaka Takuji²⁵,Seki Akihiro⁶,Ishii Tadashi⁶

Affiliation:

1. Department of Medical Oncology, Kyorin University School of Medicine, Tokyo

2. Independent Advisory Board for Erlotinib, Tokyo

3. Department of Respiratory Medicine and Oncology, Nippon Medical School Graduate School of Medicine, Tokyo

4. Department of Medical Oncology, Showa University Fujigaoka Hospital, Tokyo

5. Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo

6. Chugai Pharmaceuticals Ltd, Tokyo, Japan

Funder

Chugai Pharmaceutical Co. Ltd

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/47/9/832/26567548/hyx075.pdf

Reference30 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

2. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297;Berlin;J Clin Oncol,2002

3. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale;Colucci;Cancer,2002

4. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate;Rocha Lima;J Clin Oncol,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database;Int. Journal of Clinical Pharmacology and Therapeutics;2024-02-01

2. EGFR Inhibitors (Gefitinib, Erlotinib, Afatinib, and Osimertinib);Analysis File of Drug-Induced Lung Injury;2024

3. Understanding Drug-Induced Lung Injuries;Analysis File of Drug-Induced Lung Injury;2024

4. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer;Internal Medicine;2022-12-15

5. Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients;Journal of Pharmaceutical Health Care and Sciences;2022-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3